In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on Genprex Inc (GNPX), with a price target of $3. The company’s shares opened today at $1.30, equals to its 52-week low of $1.30.
Palomeque noted:
“Genprex reported 3Q18 with a net loss of ($2.2M) and ended the period with $10.3M in cash and cash equivalents.”
According to TipRanks.com, Palomeque has currently no stars on a ranking scale of 0-5 stars, with an average return of -13.6% and a 26.9% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as Soleno Therapeutics Inc, VistaGen Therapeutics, and Anavex Life Sciences.
Genprex Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $19.45 and a one-year low of $1.30. Currently, Genprex Inc has an average volume of 45.12K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
